Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial (Q38424831)

From Wikidata

Jump to navigation Jump to search

scientific article published on 14 April 2015

Language	Label	Description	Also known as
English	Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial	scientific article published on 14 April 2015

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

phase III clinical trial

0 references

multicenter clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

chronic lymphocytic leukemia

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

object named as

Peter Hillmen

0 references

Sebastian Grosicki

6

object named as

Sebastian Grosicki

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

2

object named as

Tadeusz Robak

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Janusz Kłoczko

5

object named as

Janusz Kloczko

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

author name string

Ann Janssens

3

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

K Govind Babu

4

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Michael Doubek

7

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Panagiotis Panagiotidis

8

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Eva Kimby

9

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Anna Schuh

10

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Andrew R Pettitt

11

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Thomas Boyd

12

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Marco Montillo

13

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Ira V Gupta

14

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Oliver Wright

15

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Iestyn Dixon

16

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Jodi L Carey

17

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Chai-Ni Chang

18

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Steen Lisby

19

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Astrid McKeown

20

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Fritz Offner

21

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

COMPLEMENT 1 Study Investigators

22

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

language of work or name

0 references

publication date

14 April 2015

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

385

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

9980

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

1873-1883

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Chronic lymphocytic leukemia in less fit patients: "slow-go".

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960027-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960027-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960027-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960027-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960027-7

7 January 2021

based on heuristic

inferred from DOI database lookup

First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960027-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960027-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960027-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960027-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Killing of CLL and NHL cells by rituximab and ofatumumab under limited availability of complement.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960027-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960027-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960027-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960027-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960027-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960027-7

7 January 2021

based on heuristic

inferred from DOI database lookup

ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960027-7

7 January 2021

based on heuristic

inferred from DOI database lookup

International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960027-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Comorbidity and functional status are independent in older cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960027-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960027-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960027-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960027-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A manual of guidelines to score the modified cumulative illness rating scale and its validation in acute hospitalized elderly patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960027-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Computed tomography scans do not improve the predictive power of 1996 national cancer institute sponsored working group chronic lymphocytic leukemia response criteria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960027-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960027-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960027-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of elderly patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960027-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960027-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960027-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960027-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960027-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960027-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960027-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960027-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960027-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(15)60027-7

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38424831&oldid=2087704696"